Dr. Gradishar Discusses the Treatment of HER2+ Breast Cancer

William J. Gradishar, MD
Published: Friday, Mar 30, 2018



William J. Gradishar, MD, interim chief of hematology and oncology, Department of Medicine, Betsy Bramsen Professorship of Breast Oncology, professor of medicine (hematology and oncology), Northwestern University's Feinberg School of Medicine, discusses the treatment of patients with HER2-positive breast cancer.

There are some patients who are not candidates for chemotherapy, or cannot tolerate it due to other medical comorbities, says Gradishar. Other options for these patients would be giving both hormonal therapy and HER2-targeted therapy simultaneously, such as lapatinib (Tykerb) and letrozole or anastrozole and trastuzumab (Herceptin).

More recently, dual targeting of HER2 along with an hormonal therapy has shown promise as a treatment for these patients. The phase III results from the ALTERNATIVE trial showed the median progression-free survival was 11 months (95% CI, 8.3-13.8) for postmenopausal women with hormone receptor-positive, HER2-positive metastatic breast cancer assigned to lapatinib plus trastuzumab plus an aromatase inhibitor (AI) compared with 5.7 months (95% CI, 5.5-8.4) for patients assigned to trastuzumab plus an AI.

There has also been work looking at combining hormonal therapy with CDK 4/6 inhibitors and HER2-targeted therapy, Gradishar adds.
SELECTED
LANGUAGE


William J. Gradishar, MD, interim chief of hematology and oncology, Department of Medicine, Betsy Bramsen Professorship of Breast Oncology, professor of medicine (hematology and oncology), Northwestern University's Feinberg School of Medicine, discusses the treatment of patients with HER2-positive breast cancer.

There are some patients who are not candidates for chemotherapy, or cannot tolerate it due to other medical comorbities, says Gradishar. Other options for these patients would be giving both hormonal therapy and HER2-targeted therapy simultaneously, such as lapatinib (Tykerb) and letrozole or anastrozole and trastuzumab (Herceptin).

More recently, dual targeting of HER2 along with an hormonal therapy has shown promise as a treatment for these patients. The phase III results from the ALTERNATIVE trial showed the median progression-free survival was 11 months (95% CI, 8.3-13.8) for postmenopausal women with hormone receptor-positive, HER2-positive metastatic breast cancer assigned to lapatinib plus trastuzumab plus an aromatase inhibitor (AI) compared with 5.7 months (95% CI, 5.5-8.4) for patients assigned to trastuzumab plus an AI.

There has also been work looking at combining hormonal therapy with CDK 4/6 inhibitors and HER2-targeted therapy, Gradishar adds.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x